Intercept Pharmaceuticals is one step closer to getting FDA approval for the first-ever NASH drug

Intercept Pharmaceuticals Inc. announced Tuesday that a potential therapy for the fatty liver disease known as NASH had achieved its primary goal in a Phase 3 trial, a week after Gilead Sciences Inc. announced a competing trial had failed.